Biogen Still Has Competitive Advantages in Neurology, but Its Moat Looks Narrow
We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...
New research uncovers brain changes in Parkinson's disease
Researchers at Karolinska Institutet have discovered new insights into brain changes in Parkinson's disease using advanced ...
From fingers to toes, wearable and vibrating technology could help Parkinson's patients
Fingernail-sized vibrating gadgets, similar to the tiny devices that make your cellphone buzz, could help people with ...
The surprising way scientists say smokers can ease nicotine withdrawal
Now, scientists in Korea have discovered that the Parkinson’s disease drug procyclidine can alleviate physical symptoms of ...
European Medical Journal15h
New AI Model Detects Early Signs of Parkinson’s with High Accuracy
AI predicts Parkinson’s disease using medical and prescription data, enhancing early diagnosis and research into new ...
Anavex projects EMA feedback on Alzheimer's drug by year-end 2025
Q1 2025 Management View CEO Christopher Missling highlighted key updates on the Alzheimer's treatment, blarcamesine. He emphasized the potential of the drug to offer "a scalable treatment alternative ...